Sanofi Stays Bullish On Synthorx IL-2 Drug, But It’s Early Days
Drug Maker Presents Initial Phase I Data At AACR
In an interview, oncology development exec Peter Adamson reiterated the company’s view that THOR-707 is best-in-class, but more data are needed to see where its efficacy stands amid the IL-2 herd.
